<DOC>
	<DOCNO>NCT00805233</DOCNO>
	<brief_summary>This open-label , randomize , Phase II research study look see whether investigational treatment combine bromfenac ophthalmic drop ranibizumab intravitreal injection safe effective treat wet AMD compare ranibizumab alone .</brief_summary>
	<brief_title>Combination Ranibizumab Bromfenac Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description>Age Related Macular Degeneration ( AMD ) lead cause blindness adult age 50 year . It cause permanent loss eyesight due deterioration macula . Ranibizumab monotherapy currently standard care neovascular AMD patient . Inflammation believe play important role AMD . Currently , MD 's investigate modulate inflammation component AMD intra-ocular steroid although high rate steroid associate adverse event , glaucoma , cataracts endophthalmitis . Bromfenac non-steroidal anti-inflammatory drug ( NSAIDS ) currently approve treatment inflammation follow cataract surgery . In combination intravitreal ranibizumab , bromfenac may also provide anti-inflammatory effect may safer alternative steroid .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Patients active neovascular AMD If patient bilateral disease qualifies study , eye may include Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Current recent participation another simultaneous investigational drug trial may exclusionary investigator 's discretion Concurrent eye disease study eye could compromise visual acuity ( e.g. , diabetic retinopathy , advanced glaucoma ) Previous intravitreal steroid antiVEGF therapy within last 3 month . Patients concurrent corneal epithelial disruption erosion Patients immune deficiency would affect ability cornea heal Patients know sensitivity component formulation investigation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Neovascular</keyword>
	<keyword>AMD</keyword>
	<keyword>Treatment</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Bromfenac</keyword>
</DOC>